FealtySign in

Merck & Co., Inc.

(MRK)

CIK 310158 · SEC filings only

Not gradedDividend record
shown as history
company entity
55 dividend record entries

Dividend record — shown as history, not graded

A declared dividend is a reported fact, not a promise we grade. Here's the record — raises, holds, and cuts — each linked to its source filing.

Dividend record

55 declarations · 15 raised · 36 held · 0 cut · held 51 quarters

  1. HELD$0.8500/shperiod ended 2026-06-30Filing ↗
  2. RAISED$0.8500/shperiod ended 2026-03-31Filing ↗
  3. HELD$0.8100/shperiod ended 2025-09-30Filing ↗
  4. HELD$0.8100/shperiod ended 2025-06-30Filing ↗
  5. RAISED$0.8100/shperiod ended 2025-03-31Filing ↗
  6. HELD$0.7700/shperiod ended 2024-09-30Filing ↗
  7. HELD$0.7700/shperiod ended 2024-06-30Filing ↗
  8. RAISED$0.7700/shperiod ended 2024-03-31Filing ↗
  9. HELD$0.7300/shperiod ended 2023-09-30Filing ↗
  10. HELD$0.7300/shperiod ended 2023-06-30Filing ↗
  11. RAISED$0.7300/shperiod ended 2023-03-31Filing ↗
  12. HELD$0.6900/shperiod ended 2022-09-30Filing ↗
Descriptive dividend record — every entry links to its source filing. Not graded (a declared dividend is a reported fact, not a promise). Full methodology →
CGuidance record
grade
company entity
12 resolved promises

Resolved promises

Pro

Full say-do history

Free scorecards show the 12 most recent resolved guidance promises. See the complete multi-year record with Pro.

See Pro →

Guidance shown, not graded (20)

These are non-GAAP forecasts. There is no comparable GAAP figure in SEC XBRL to check them against, so we show what was said — with its source filing — but never score it.

  1. eps guidance fy · Aug 4, 2026
    now expects full-year 2026 non-GAAP EPS to be between $2.66 and $2.76
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  2. eps guidance fy · Feb 3, 2026
    Expects Non-GAAP EPS To Be Between $5.00 and $5.15
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  3. eps guidance fy · Oct 30, 2025
    Raises and Narrows Expected Non-GAAP EPS Range To Be Between $8.93 and $8.98
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  4. eps guidance fy · Jul 29, 2025
    Narrows Expected Non-GAAP EPS Range To Be Between $8.87 and $8.97
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  5. eps guidance fy · Apr 24, 2025
    Now Expects Non-GAAP EPS To Be Between $8.82 and $8.97
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  6. eps guidance fy · Feb 4, 2025
    Expects Non-GAAP EPS To Be Between $8.88 and $9.03
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  7. eps guidance fy · Oct 31, 2024
    Now Expects Non-GAAP EPS To Be Between $7.72 and $7.77
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  8. eps guidance fy · Apr 25, 2024
    Merck now expects its full-year non-GAAP EPS to be between $8.53 and $8.65
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  9. eps guidance fy · Feb 1, 2024
    Expects Non-GAAP EPS To Be Between $8.44 and $8.59
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  10. eps guidance fy · Aug 1, 2023
    Now Expects Non-GAAP EPS To Be Between $2.95 and $3.05
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  11. eps guidance fy · Apr 27, 2023
    Merck is raising and narrowing its full-year 2023 non-GAAP EPS range to be between $6.88 and $7.00
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  12. eps guidance fy · Feb 2, 2023
    Merck expects full-year 2023 non-GAAP EPS to be between $6.80 and $6.95
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  13. eps guidance fy · Jul 28, 2022
    Merck is narrowing its expected full-year 2022 non-GAAP EPS range to be between $7.25 and $7.35
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  14. eps guidance fy · Apr 28, 2022
    raising and narrowing its full-year 2022 non-GAAP EPS range to be between $7.24 and $7.36
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  15. eps guidance fy · Feb 3, 2022
    Expects Non-GAAP EPS to be Between $7.12 and $7.27
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  16. eps guidance fy · Oct 28, 2021
    full-year 2021 to be between $5.65 and $5.70
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  17. eps guidance fy · Jul 29, 2021
    Expects Full-Year 2021 Non-GAAP EPS to be Between $5.47 and $5.57
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  18. eps guidance fy · Feb 4, 2021
    Merck expects full-year 2021 non-GAAP EPS to be between $6.48 and $6.68
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  19. eps guidance fy · Oct 27, 2020
    Merck narrowed and raised its full-year 2020 non-GAAP EPS range to be between $5.91 and $6.01
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  20. eps guidance fy · Apr 30, 2019
    Merck narrowed and raised its full-year 2019 non-GAAP EPS range to be between $4.67 and $4.79
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗

Open promises (1) · 18 superseded

Open · revenue guidance fy

now anticipates full-year 2026 sales to be between $66.3 billion and $67.3 billion

resolves in ~198 daysreceipt →
Superseded · revenue guidance fy

Merck now expects its full-year 2024 sales to be between $63.1 billion and $64.3 billion

revised by a later guidancereceipt →
Superseded · eps guidance fy

Expects Full-Year 2022 GAAP EPS to be Between $5.76 and $5.91

revised by a later guidancereceipt →
Superseded · eps guidance fy

raising and narrowing its full-year 2022 GAAP EPS range to be between $5.90 and $6.02

revised by a later guidancereceipt →
Superseded · revenue guidance fy

Anticipates Worldwide Sales To Be Between $64.1 Billion and $65.6 Billion

revised by a later guidancereceipt →
Superseded · eps guidance fy

Expects Full-Year 2021 GAAP EPS to be Between $4.24 and $4.34

revised by a later guidancereceipt →
Superseded · eps guidance fy

Merck expects full-year 2023 GAAP EPS to be between $5.86 and $6.01

revised by a later guidancereceipt →
Superseded · revenue guidance fy

Now Expects Sales To Be Between $65.8 Billion and $67.0 Billion

revised by a later guidancereceipt →
Superseded · revenue guidance fy

Anticipates Full-Year 2023 Worldwide Sales To Be Between $57.2 Billion and $58.7 Billion

revised by a later guidancereceipt →
Superseded · revenue guidance fy

Narrows and Raises Estimated Full-Year 2021 Revenue Range to be Between $46.4 Billion and $47.4 Billion

revised by a later guidancereceipt →
Superseded · revenue guidance fy

Anticipates Worldwide Sales To Be Between $62.7 Billion and $64.2 Billion

revised by a later guidancereceipt →
Superseded · eps guidance fy

Merck expects full-year 2021 GAAP EPS to be between $5.52 and $5.72

revised by a later guidancereceipt →
Superseded · revenue guidance fy

Narrows Expected Worldwide Sales Range To Be Between $64.3 Billion and $65.3 Billion

revised by a later guidancereceipt →
Superseded · revenue guidance fy

Anticipates Worldwide Sales To Be Between $65.5 Billion and $67.0 Billion

revised by a later guidancereceipt →
Superseded · revenue guidance fy

Merck now expects full-year 2023 sales to be between $57.7 billion and $58.9 billion

revised by a later guidancereceipt →
Superseded · revenue guidance fy

full-year revenue estimated to be between $56.9 billion and $58.1 billion

revised by a later guidancereceipt →
Superseded · revenue guidance fy

Continues To Expect Worldwide Sales To Be Between $64.1 Billion and $65.6 Billion

revised by a later guidancereceipt →
Superseded · revenue guidance fy

Merck anticipates full-year 2021 revenue to be between $51.8 billion and $53.8 billion

revised by a later guidancereceipt →
Superseded · revenue guidance fy

Anticipates Full-Year 2022 Worldwide Sales to be Between $56.1 Billion and $57.6 Billion

revised by a later guidancereceipt →

Credibility timeline

BEAT · Feb 26, 2020MISSED · Feb 26, 2020MISSED · Feb 25, 2021KEPT · Feb 25, 2021BEAT · Feb 25, 2022BEAT · Feb 25, 2022MISSED · Feb 24, 2023BEAT · Feb 24, 2023BEAT · Feb 26, 2024MISSED · Feb 26, 2024BEAT · Feb 25, 2025BEAT · Feb 24, 2026
20202026
Timeline as a list
  • Feb 26, 2020BEATMerck narrowed and raised its full-year 2019 revenue range to be between $43.9 billion and $45.1 billion
  • Feb 26, 2020MISSEDMerck narrowed and raised its full-year 2019 GAAP EPS range to be between $4.02 and $4.14
  • Feb 25, 2021MISSEDMerck narrowed and lowered its full-year 2020 GAAP EPS range to be between $4.55 and $4.65
  • Feb 25, 2021KEPTMerck narrowed and raised its full-year 2020 revenue range to be between $47.6 billion and $48.6 billion
  • Feb 25, 2022BEATfull-year 2021 GAAP EPS range to be between $4.71 and $4.76
  • Feb 25, 2022BEATfull-year 2021 revenue estimated to be between $47.4 billion and $47.9 billion
  • Feb 24, 2023MISSEDMerck expects its estimated full-year 2022 GAAP EPS to be between $5.89 and $5.99
  • Feb 24, 2023BEATCompany Raises and Narrows Expected Full-Year 2022 Worldwide Sales Range To Be Between $57.5 Billion and $58.5 Billion
  • Feb 26, 2024BEATRaises and Narrows Expected Worldwide Sales Range To Be Between $58.6 Billion and $59.6 Billion
  • Feb 26, 2024MISSEDMerck is lowering and narrowing its full-year 2023 GAAP EPS range to be between $5.85 and $5.97
  • Feb 25, 2025BEATNarrows Expected Worldwide Sales Range To Be Between $63.6 Billion and $64.1 Billion
  • Feb 24, 2026BEATNow Expects Worldwide Sales To Be Between $64.5 Billion and $65.0 Billion
12 resolved guidance promises · 20dropped (couldn't be resolved on a consistent basis) · resolver resolver-v3 · score score-v1. Every verdict links to its source filing. Full methodology →